Efficiency and accelerating clinical trial timelines have emerged as key themes at this year’s annual SCOPE Summit in Orlando, FL. The opening keynote panel of the event moderated by Jeremy Goldberg, ...

Holly Leslie, vice president of services at Ledger Run, explains why site selectivity is not yet universal, but increasingly ...

Getz K, Barr E. Aligning Purpose, Innovation, and Operational Excellence in Clinical Development. SCOPE Summit 2026. February 3, 2026. Stay current in clinical research with Applied Clinical Trials, ...

Otis Johnson, PhD, MPA, founder and principal consultant at Vantix Operations, discusses how ESG is evolving from a reporting ...

Charlie Paterson, partner at PA Consulting, outlines how limited FDA guidance on innovative designs, decentralized models, ...

Raja Shankar, VP of machine learning at IQVIA, explains how AI-driven trial simulation and automation are beginning to influence decision-making across every phase of clinical development.

Today's biopharmaceutical landscape demands a fundamental rethinking of outsourcing approaches that embrace collaboration, flexibility, and teams willing to meet halfway.

Some organizations are considering ex-US studies for initial phases. Even with initiatives like the single pivotal trial concept, confidence requirements may still demand larger samples and longer ...

Today's biopharmaceutical landscape demands a fundamental rethinking of outsourcing approaches that embrace collaboration, flexibility, and teams willing to meet halfway.

Today's biopharmaceutical landscape demands a fundamental rethinking of outsourcing approaches that embrace collaboration, flexibility, and teams willing to meet halfway.

Beyond the design, if enrollment slows due to seasonal effects or difficulty finding a niche patient group, a robust design activates a contingency plan that dynamically adjusts site selection based ...

Certain low-risk or mature devices may see reduced trial requirements, but the broader trend is toward augmenting—not ...